Edition:
India

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.69EUR
18 Dec 2017
Change (% chg)

€0.29 (+2.34%)
Prev Close
€12.40
Open
€12.49
Day's High
€12.78
Day's Low
€12.43
Volume
54,071
Avg. Vol
73,359
52-wk High
€22.50
52-wk Low
€11.25

Select another date:

Wed, Nov 15 2017

BRIEF-Nanobiotix Q3 revenue down at 33.0‍​ million euros

* Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)

BRIEF-Nanobiotix completes new share issue for about 27.2 million euros

* NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES

BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3

* NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.‍​

* PLANS TO CONDUCT ITS FIRST CLINICAL TRIAL WITH NBTXR3 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.‍​

BRIEF-Nanobiotix H1 net loss widens to 12.2 million euros

* H1 NET LOSS EUR 12.2 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO

BRIEF-Nanobiotix Q2 revenue down at 58,645 euros

* H1 RENTAL REVENUE EUR 91.5 MLN VS EUR 91.4 MLN YR AGO Source text: http://bit.ly/2tJ0z7p Further company coverage: (Gdynia Newsroom)

Select another date: